Overview

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami
Treatments:
Sunitinib